Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P100
Near historical high
vs 2Y Ago
13.5x
Strong expansion
Streak
3 yr
Consecutive growthAccelerating
PeriodValue
2024133.27%
202369.76%
20229.86%
20210.00%